OBJECTIVE:Cancer patients who smoke are advised to quit smoking to reduce treatment complications and future cancer risk. This study's main objective was to evaluate the efficacy of a novel, presurgical cessation intervention in newly diagnosed cancer patients scheduled for surgical hospitalization. METHOD: We conducted a parallel-arm, randomized controlled trial comparing the efficacy of our hospital-based, tobacco cessation "best practices" treatment model (BP; cessation counseling and nicotine replacement therapy) with BP enhanced by a behavioral tapering regimen (scheduled reduced smoking; BP + SRS) administered by a handheld computer before hospitalization for surgery. Cessation outcomes were short (hospital admission and 3 months) and longer-term (6 months) biochemically verified smoking abstinence. We hypothesized that BP + SRS would be superior to BP alone. One hundred eighty-five smokers were enrolled. RESULTS: Overall, 7-day-point prevalence, confirmed abstinence rates at 6 months for BP alone (32%) and BP + SRS (32%) were high; however, no main effect of treatment was observed. Patients who were older and diagnosed with lung cancer were more likely to quit smoking. CONCLUSION: Compared to best practices for treating tobacco dependence, a presurgical, scheduled reduced smoking intervention did not improve abstinence rates among newly diagnosed cancer patients.reserved).
RCT Entities:
OBJECTIVE:Cancerpatients who smoke are advised to quit smoking to reduce treatment complications and future cancer risk. This study's main objective was to evaluate the efficacy of a novel, presurgical cessation intervention in newly diagnosed cancerpatients scheduled for surgical hospitalization. METHOD: We conducted a parallel-arm, randomized controlled trial comparing the efficacy of our hospital-based, tobacco cessation "best practices" treatment model (BP; cessation counseling and nicotine replacement therapy) with BP enhanced by a behavioral tapering regimen (scheduled reduced smoking; BP + SRS) administered by a handheld computer before hospitalization for surgery. Cessation outcomes were short (hospital admission and 3 months) and longer-term (6 months) biochemically verified smoking abstinence. We hypothesized that BP + SRS would be superior to BP alone. One hundred eighty-five smokers were enrolled. RESULTS: Overall, 7-day-point prevalence, confirmed abstinence rates at 6 months for BP alone (32%) and BP + SRS (32%) were high; however, no main effect of treatment was observed. Patients who were older and diagnosed with lung cancer were more likely to quit smoking. CONCLUSION: Compared to best practices for treating tobacco dependence, a presurgical, scheduled reduced smoking intervention did not improve abstinence rates among newly diagnosed cancerpatients.reserved).
Authors: Adam O Goldstein; Carol E Ripley-Moffitt; Donald E Pathman; Katharine M Patsakham Journal: Nicotine Tob Res Date: 2012-04-11 Impact factor: 4.244
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: Diana S Hoover; Claire A Spears; Damon J Vidrine; Joan L Walker; Ya-Chen Tina Shih; David W Wetter Journal: Am J Health Behav Date: 2019-05-01
Authors: Kathryn I Pollak; Pauline Lyna; Xiaomei Gao; Devon Noonan; Santiago Bejarano Hernandez; Sonia Subudhi; Geeta K Swamy; Laura J Fish Journal: Nicotine Tob Res Date: 2020-06-12 Impact factor: 4.244
Authors: Elyse R Park; Jamie S Ostroff; Giselle K Perez; Kelly A Hyland; Nancy A Rigotti; Sarah Borderud; Susan Regan; Alona Muzikansky; Emily R Friedman; Douglas E Levy; Susan Holland; Justin Eusebio; Lisa Peterson; Julia Rabin; Jacob Miller-Sobel; Irina Gonzalez; Laura Malloy; Maureen O'Brien; Suhana de León-Sanchez; C Will Whitlock Journal: Contemp Clin Trials Date: 2016-07-19 Impact factor: 2.226
Authors: Diana B Díaz; Thomas H Brandon; Steven K Sutton; Lauren R Meltzer; Hannah J Hoehn; Cathy D Meade; Paul B Jacobsen; Judith C McCaffrey; Eric B Haura; Hui-Yi Lin; Vani N Simmons Journal: Contemp Clin Trials Date: 2016-07-25 Impact factor: 2.226